PTC Therapeutics Enters into Agreement to Sell Priority Review Voucher for $150 Million

WARREN, N.J., Nov. 27, 2024 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) announced today that it has entered into an agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for $150 million upon the closing of the transaction. PTC was granted the PRV on...